Is SpyGlass Pharma, Inc. Common Stock (SGP) a Buy, Sell, or Hold?
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
$20.6 USD
$0.61 (3.05%)
- Volume
- 146.38K
- Average Volume
- 98.95K
- Market Capitalization
- $688.73M
- P/E Ratio
- -19.25
- Dividend Yield
- 0.00%
- Price Target
- $62.00
- Year High
- $32.44
- Year Low
- $17.06
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $38.00
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Patrick H. Mooney |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | SGP |
| CUSIP | 85220G109 |
| CIK | 0001778922 |
| Web | http://www.spyglasspharma.com |
| Phone | 1 949 535 0588 |
| Currency | USD |
| Employees | 65 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 38.00 |
| Quick Ratio | 38.00 |
| Cash Ratio | 35.83 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.20 |
| Price / Cash Flow | -28.73 |
| Price / Book | 1.64 |
Price Target and Rating
| Average Stock Price Forecast | $62.00 |
| High Stock Price Forecast | $62.00 |
| Low Stock Price Forecast | $62.00 |
| Forecast Upside/Downside | -66.77% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.19 |
| Trailing P/E Ratio | -19.25 |
| PEG Ratio | -0.19 |
| P/E Growth | -0.19 |
| Net Income | $-39.87M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -123.53% |
| Return on Assets | -10.21% |
Financials Score
| AltmanZ Score | |
| Piotroski Score | |
| Working Capital | - |
| Total Assets | - |
| Ebit | - |
| Market Cap | - |
| Total Liabilities | - |
Poll Results
About SpyGlass Pharma, Inc. Common Stock (NASDAQ:SGP) Stock
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA. ...
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
2026-06-15 08:00:00
ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as general counsel. Ms. Treviño brings significant business-oriented legal experience and leadership that results in operating excellence for publicly traded companies at various stages of growth.
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
2026-06-02 08:00:00
ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder as vice president, marketing.
SpyGlass Pharma to Participate in Upcoming Investor Conferences
2026-05-21 08:00:00
ALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology Forum Date: Tuesday, May 26, 2026Time: 2:00 p.m.
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
2026-05-18 08:00:00
ALISO VIEJO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced that the American Medical Association's (AMA) CPT® (Current Procedural Terminology) Editorial Panel approved a new add-on Category III CPT code for attachment and insertion of intraocular lens prosthesis-mounted drug-eluting implant, based on the application submitted for the Bimatoprost Drug Pad-IOL System (BIM-IOL System), in conjunction with established Category I cataract surgery procedure codes.
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-14 16:05:00
ALISO VIEJO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the first quarter ended March 31, 2026.
Analyzing Longevity Health (NASDAQ:XAGE) and Spyglass Pharma (NASDAQ:SGP)
2026-04-15 02:29:11
Spyglass Pharma (NASDAQ: SGP - Get Free Report) and Longevity Health (NASDAQ: XAGE - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership. Institutional and Insider Ownership 24.2% of Longevity
Frequently Asked Questions
-
What is the current SpyGlass Pharma, Inc. Common Stock (SGP) stock price?
-
SpyGlass Pharma, Inc. Common Stock(NASDAQ:SGP) stock price is $20.6 in the last trading session. During the trading session, SGP stock reached the peak price of $32.44 while $17.06 was the lowest point it dropped to. The percentage change in SGP stock occurred in the recent session was 3.05% while the dollar amount for the price change in SGP stock was $0.61.
-
SGP's industry and sector of operation?
-
The NASDAQ listed SGP is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SGP?
-
Shannon Trevino | General Counsel
Chetan Pujara | Chief Research & Development Officer
Glenn Sussman | Co-founder & Chief Technology Advisor
James Robert Dennewill Jr. | Chief Operating Officer
Patrick H. Mooney | CEO & Director -
How many employees does SGP have?
-
Number of SGP employees currently stands at 65. SGP operates from 27061 Aliso Creek Road, Aliso Viejo, CA 92656, US.
-
Link for SGP official website?
-
Official Website of SGP is: http://www.spyglasspharma.com
-
How do I contact SGP?
-
SGP could be contacted at phone #1 949 535 0588 and can also be accessed through its website. SGP operates from 27061 Aliso Creek Road, Aliso Viejo, CA 92656, US.
-
How many shares of SGP are traded daily?
-
The average number of SGP shares traded daily for last 3 months was 98.95K.
-
What is the market cap of SGP currently?
-
The market value of SGP currently stands at $688.73M with its latest stock price at $20.6